Overall Survival with palbociclib and fulvestrant in Women with HR+/HER2- ABC: updated exploratory analyses of PALOMA-3, a double-blind, phase iii randomized study was written by Cristofanilli, Massimo;Rugo, Hope S.;Im, Seock-Ah;Slamon, Dennis J.;Harbeck, Nadia;Bondarenko, Igor;Masuda, Norikazu;Colleoni, Marco;Demichele, Angela;Loi, Sherene;Iwata, Hiroji;O’leary, Ben;Andre, Fabrice;Loibl, Sibylle;Bananis, Eustratios;Liu, Yuan;Huang, Xin;Kim, Sindy;Frean, Maria Jose Lechuga;Turner, Nicholas C.. And the article was included in Clinical Cancer Research in 2022.Product Details of 571190-30-2 This article mentions the following:
Purpose: To conduct an updated exploratory anal. of overall survival (OS) with a longer median follow-up of 73.3 mo and evaluate the prognostic value of mol. anal. by circulating tumor DNA (ctDNA). Patients and methods: Patients with hormone receptor-pos./human epidermal growth factor receptor 2-neg. (HR+/HER2-) advanced breast cancer (ABC) were randomized 2:1 to receive palbociclib (125 mg orally/day; 3/1 wk schedule) and fulvestrant (500 mg i.m.) or placebo and fulvestrant. This OS anal. was performed when 75% of enrolled patients died (393 events in 521 randomized patients). ctDNA anal. was performed among patients who provided consent. Results: At the data cutoff (August 17, 2020), 258 and 135 deaths occurred in the palbociclib and placebo groups, resp. The median OS [95% confidence interval (CI)] was 34.8 mo (28.8-39.9) in the palbociclib group and 28.0 mo (23.5-33.8) in the placebo group (stratified hazard ratio, 0.81; 95% CI, 0.65-0.99). The 6-yr OS rate (95% CI) was 19.1% (14.9-23.7) and 12.9% (8.0-19.1) in the palbociclib and placebo groups, resp. Favorable OS with palbociclib plus fulvestrant compared with placebo plus fulvestrant was observed in most subgroups, particularly in patients with endocrine-sensitive disease, no prior chemotherapy for ABC and low circulating tumor fraction and regardless of ESR1, PIK3CA, or TP53 mutation status. No new safety signals were identified. Conclusions: The clin. meaningful improvement in OS associated with palbociclib plus fulvestrant was maintained with >6 years of follow-up in patients with HR+/HER2- ABC, supporting palbociclib plus fulvestrant as a standard of care in these patients. In the experiment, the researchers used many compounds, for example, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one (cas: 571190-30-2Product Details of 571190-30-2).
6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one (cas: 571190-30-2) belongs to piperazine derivatives. Piperazine was first introduced as an anthelmintic in 1953. Piperazine compounds mediate their anthelmintic action by generally paralyzing parasites, allowing the host body to easily remove or expel the invading organism. Two common salts in the form of which piperazine is usually prepared for pharmaceutical or veterinary purposes are the citrate, 3C4H10N2.2C6H8O7 (i.e. containing 3 molecules of piperazine to 2 molecules of citric acid), and the adipate, C4H10N2.C6H10O4 (containing 1 molecule each of piperazine and adipic acid).Product Details of 571190-30-2
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics